• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sanofi sues Nordisk over Tresiba marketing claims in U.S.

December 28, 2016 By Sarah Faulkner

Sanofi sues Nordisk over Tresiba marketing claims in U.S.Sanofi (NYSE:SNY) said yesterday that it is suing competitor Novo Nordisk (NYSE:NVO) for “misleading” marketing materials that claim Sanofi’s insulin drugs Lantus and Toujeo will be “blocked” by U.S. pharmacy benefit manager CVS Caremark in January and that patients should switch to Nordisk’s Tresiba.

CVS is replacing both Sanofi’s and Nordisk’s drugs with Eli Lilly’s Basaglar on its standard formulary, but Sanofi said that many health plans don’t follow CVS’s standard list and even those that do will probably continue to cover the company’s drugs.

“(W)e believe Novo’s statements concerning CVS Caremark’s formulary decision on Lantus and Toujeo coverage contain false and misleading claims about the continued availability of Lantus and Toujeo,” a Sanofi spokeswoman said in an emailed statement, according to Reuters. 

Nordisk has not released a formal comment on the matter.

According to the complaint filed in the U.S. District Court for the District of New Jersey, Sanofi is seeking an order to force Nordisk to pay unspecified money damages and withdraw the marketing materials.

Other insurers, such as UnitedHealth Group Inc., have put pressure on Sanofi’s U.S. diabetes business in recent months, replacing Lantus and Toujeo with the cheaper biosimilar Basaglar.

Until recently, Sanofi has been involved in talks with Actelion (VTX:ATLN) in an attempt to buy the Swiss biotech firm. Sanofi jumped at the chance to make a deal after Johnson & Johnson (NYSE:JNJ) backed out of negotiations, but recent reports confirmed that the US healthcare group has re-entered exclusive talks with Actelion, kicking Sanofi to the curb.

The French drugmaker was eager to land a deal after it lost out to Pfizer in a pursuit for Medivation earlier this year.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Novo Nordisk, Sanofi-Aventis

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS